Form 4: Inhibrx Biosciences Director Jon Faiz Kayyem Gifts Shares to Family and Trusts

Director Jon Faiz Kayyem of Inhibrx Biosciences reports gifting shares of common stock to family members and trusts, with no monetary transaction involved.

Summary

• On June 24, 2024, Jon Faiz Kayyem, a director of Inhibrx Biosciences, filed a Form 4 with the SEC.
• The filing reports a gift of 89,050 shares of Inhibrx Biosciences common stock from The Jon F. Kayyem and Paige Gates-Kayyem Family Trust.
• These shares were gifted to the reporting person's children, relatives, and other individuals.
• 40,000 shares were gifted to adult children not residing in the reporting person's household.
• 22,825 shares were gifted to trusts for the benefit of individuals not residing in the reporting person's household.
• 4,150 shares were gifted to relatives not residing in the reporting person's household.
• 2,075 shares were gifted to a UTMA for the benefit of a minor not residing in the reporting person's household.
• Additionally, 10,000 shares each were gifted to custodial accounts for the benefit of Child A and Child B, managed by the reporting person.
• The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
• Following these transactions, the Jon F. Kayyem and Paige Gates-Kayyem Family Trust indirectly owns 1,061,360 shares.
• Child A and Child B each indirectly own 16,250 shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a gift of shares. It doesn't inherently convey positive or negative sentiment regarding the company's performance or future prospects.

Industry Context

This filing is a routine disclosure related to changes in beneficial ownership by a company insider and doesn't necessarily reflect any specific industry trend or competitive dynamic.

Stakeholder Impact

• The gifting of shares may have a minor impact on the overall shareholder base, but is unlikely to significantly affect the company's operations or financial performance.

Key Dates